BRIM BIOTECHNOLOGY, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.2 TWD | +1.46% |
|
-0.32% | +4.17% |
| 2023 | BRIM Biotechnology, Inc.(TPEX:6885) added to S&P Global BMI Index | CI |
| 2022 | BRIM Biotechnology, Inc. announced that it has received $20 million in funding | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 3,558 | 3,467 |
| Enterprise Value (EV) 1 | 2,726 | 1,775 |
| P/E ratio | -9.92 x | -4.38 x |
| Yield | - | - |
| Capitalization / Revenue | 6,763,574,335 x | 38,520,358,889 x |
| EV / Revenue | 5,182,680,798 x | 19,719,958,889 x |
| EV / EBITDA | -12.5 x | -2.56 x |
| EV / FCF | -27,835,673 x | -4,783,004 x |
| FCF Yield | -0% | -0% |
| Price to Book | 3.89 x | 2 x |
| Nbr of stocks (in thousands) | 93,254 | 115,754 |
| Reference price 2 | 38.15 | 29.95 |
| Announcement Date | 18/04/23 | 02/04/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | - | 90.76 | 0.36 | 0.526 | 0.09 |
| EBITDA 1 | -123.6 | -155.1 | -93.01 | -218 | -692.9 |
| EBIT 1 | -125.1 | -155.4 | -93.22 | -218.3 | -694.1 |
| Operating Margin | - | -171.21% | -25,893.06% | -41,506.84% | -771,250% |
| Earnings before Tax (EBT) 1 | -122 | -97.01 | -105.4 | -274.3 | -688 |
| Net income 1 | -118.8 | -87.94 | -105.4 | -274.3 | -688 |
| Net margin | - | -96.89% | -29,291.39% | -52,143.92% | -764,468.89% |
| EPS 2 | -2.020 | -1.494 | -1.778 | -3.847 | -6.843 |
| Free Cash Flow | - | -55.43 | -81.3 | -97.94 | -371.1 |
| FCF margin | - | -61.07% | -22,583.82% | -18,618.85% | -412,292.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 25/05/22 | 25/05/22 | 18/04/23 | 18/04/23 | 02/04/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 430 | 163 | 420 | 832 | 1,692 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | -55.4 | -81.3 | -97.9 | -371 |
| ROE (net income / shareholders' equity) | - | -30.6% | -28.4% | -39.4% | -51.9% |
| ROA (Net income/ Total Assets) | - | -25.5% | -14.3% | -19% | -31.9% |
| Assets 1 | - | 345.5 | 735.5 | 1,443 | 2,156 |
| Book Value Per Share 2 | 5.900 | 4.480 | 8.010 | 9.810 | 15.00 |
| Cash Flow per Share 2 | 5.900 | 1.410 | 6.700 | 8.990 | 8.190 |
| Capex 1 | 0.07 | 0.37 | 0.78 | 1.11 | 2.26 |
| Capex / Sales | - | 0.4% | 217.22% | 210.08% | 2,515.56% |
| Announcement Date | 25/05/22 | 25/05/22 | 18/04/23 | 18/04/23 | 02/04/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +4.17% | 111M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 6885 Stock
- Financials BRIM Biotechnology, Inc.
